Spring til hovednavigation
Spring til søgning
Spring til hovedindhold
Region Hovedstadens forskningsportal Forside
Hjælp og OSS
Dansk
English
Forside
Hospitaler/afdelinger
Forskere
Publikationer
Aktiviteter
Priser
Søg efter ekspertise, navn eller tilknytning
Hella Danø
Overlæge
,
Nordsjællands Hospital
,
Onkologisk og Palliativ Afd.
2010
2024
Publikationer pr. år
Vis
Fingeraftryk
Netværk
Publikationer
(8)
Lignende profiler
(12)
Fingeraftryk
Dyk ned i forskningsemnerne, hvor Hella Danø er aktive. Disse emneetiketter kommer fra dennes persons arbejder. Sammen danner de et unikt fingerprint.
Sorter
Vægt
Alfabetisk
Keyphrases
Early Breast Cancer
45%
Breast Cancer
44%
Metastatic Breast Cancer
43%
Docetaxel
43%
Cyclophosphamide
43%
Epirubicin
43%
Disease-free Survival
34%
Overall Survival
28%
Normal Breast
26%
Distant Metastasis-free Survival
23%
Anthracyclines
23%
Multigene Expression
21%
Nasal Cavity
21%
Expression Assay
21%
C-reactive Protein
21%
Xena
21%
Metronomic Therapy
21%
Navelbine
21%
Prognostic Value
21%
Internal Mammary Node Irradiation
21%
Human Epidermal Growth Factor Receptor 2 (HER2)
21%
Carcinoma
21%
Population-based Cohort Study
21%
Capecitabine
21%
Paranasal Sinuses
21%
Advanced Breast Cancer
21%
Randomized Phase III Trial
21%
Fulvestrant
21%
Phase II Study
21%
Node-positive Breast Cancer
21%
Denmark
21%
Randomized Phase II Trial
21%
Prospective Evaluation
21%
Predictive Potential
21%
Vinorelbine
21%
Adjuvant Docetaxel
21%
Confidence Interval
19%
Hazard Ratio
18%
Response Predictors
14%
Drug Response
14%
Tumor
13%
Heart Failure
13%
Sinonasal Squamous Cell Carcinoma (SNSCC)
10%
Treatment Outcome
10%
Adjusted Hazard Ratio
9%
Survival Benefit
5%
Intention-to-treat
5%
Breast Cancer Mortality
5%
All Cancer
5%
Patient-reported Toxicity
5%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
100%
Metastatic Breast Cancer
43%
Vinorelbine
43%
Docetaxel
43%
Cyclophosphamide
43%
Epirubicin
43%
Disease Free Survival
43%
Fulvestrant
21%
C Reactive Protein
21%
Capecitabine
21%
Overall Survival
20%
Anthracycline
20%
Congestive Heart Failure
14%
Neoplasm
11%
Chemotherapy
8%
Recurrent Disease
8%
Malignant Neoplasm
8%
Clinical Trial
8%
Medicine and Dentistry
Breast Cancer
65%
Internal Mammary Node
21%
Fulvestrant
21%
C Reactive Protein
21%
Cohort Analysis
21%
Drug Response
14%
Recurrent Disease
11%
Biopsy
7%
Hazard Ratio
6%
